JANX (Janux Therapeutics) Institutional Ownership: 97.89% (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

JANX Janux Therapeutics Inc JANX
47 GF Score
Price $16.10
GF Value $46.27
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Janux Therapeutics Institutional Ownership?

Janux Therapeutics JANX +0.63% 47 Institutional Ownership is 97.89% as of Aug. 07, 2026. GuruFocus rates JANX with a GF Score™ of 47/100 and a GF Value™ of $46.27 (Possible Value Trap). The stock has 5 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Janux Therapeutics's institutional ownership is 97.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Janux Therapeutics's Insider Ownership is 2.28%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Janux Therapeutics's Float Percentage Of Total Shares Outstanding is 78.07%.

Janux Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Janux Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Janux Therapeutics Institutional Ownership Chart

Janux Therapeutics Historical Data

The historical data trend for Janux Therapeutics can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 44.57 44.66 41.43 39.33 37.44 34.82 34.85 35.32 37.14 42.00
JANX
47GF Score
Janux Therapeutics Inc JANX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Janux Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 97.89% mean?
Janux Therapeutics (JANX) has a Institutional Ownership of 97.89% as of Aug. 07, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Janux Therapeutics and its competitors.
Is Janux Therapeutics' Institutional Ownership too high?
Janux Therapeutics' current Institutional Ownership is 97.89%. Overall, Janux Therapeutics has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Janux Therapeutics' Institutional Ownership compare to KURA and PHAT?
Janux Therapeutics' Institutional Ownership of 97.89% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Janux Therapeutics and its competitors. Janux Therapeutics's current Institutional Ownership is 97.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Janux Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Janux Therapeutics (JANX) is currently considered Possible Value Trap. The stock's GF Value™ is $46.27, compared to a current price of $16.10 — trading 65.2% below its estimated fair value. The current Institutional Ownership is 97.89%. Janux Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Janux Therapeutics (JANX), the current Institutional Ownership is 97.89% as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Janux Therapeutics (JANX) Overvalued in 2026?

Based on GuruFocus' analysis, Janux Therapeutics stock appears to be undervalued. The current stock price of $16.10 is trading 65.2% below its estimated GF Value™ of $46.27. GuruFocus considers Janux Therapeutics to be Possible Value Trap.

Key valuation signals for JANX:

  • Institutional Ownership: 97.89%
  • GF Value™: $46.27 vs. price of $16.10 (65.2% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the JANX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Janux Therapeutics Business Description

Address 10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, USA, 92130
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
47GF Score

Get the complete analysis for JANX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.10
Price
$46.27
GF Value